Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaccine Responses in Patients With B Cell Malignancies
NCT05170399Phase 4Recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Sep 2022
- Primary completion
- Nov 2036
- Modality
- Lipid-based Nanoparticles, Recombinant Proteins and Enzymes, Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of GSK3003899A, RSVpreF vaccine, Prevnar 20, 23-valent pneumococcal polysaccharide vaccine, Hepatitis B vaccine in respiratory syncytial virus infection (RSV), pneumococcal disease, hepatitis B (HBV), herpes zoster (HZ), sponsored by National Heart, Lung, and Blood Institute. Started Sep 2022; status: recruiting.
02
Drugs
GSK3003899ARSVpreF vaccinePrevnar 2023-valent pneumococcal polysaccharide vaccineHepatitis B vaccine
03
Conditions
respiratory syncytial virus infection (RSV)pneumococcal diseasehepatitis B (HBV)herpes zoster (HZ)
Beyond the preview
Go deeper on NCT05170399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05170399.